Substance-induced psychosis and cognitive functioning: A systematic review

Psychiatry Res. 2022 Feb:308:114361. doi: 10.1016/j.psychres.2021.114361. Epub 2021 Dec 28.

Abstract

Longitudinal studies of substance-induced psychosis (SIP) suggest that approximately 11-46% of persons will progress to schizophrenia with differential risk of progression depending on the type of substance used. The findings suggest SIP may be a distinct variant of a psychotic disorder, yet SIP is understudied and the disease expression is not well characterized, particularly the cognitive phenotype. There is some evidence for cognitive dysfunction in SIP, but a synthesis of this literature has not been undertaken. We systematically reviewed all empirical research (up to December 31, 2020) that examined cognition in SIP using clinical neuropsychological measures. The cognitive outcomes are summarized by type of SIP (methamphetamine, other stimulants, alcohol, cannabis, undifferentiated). There was evidence for global and domain-specific cognitive dysfunction in SIP compared to controls and non-psychotic persons who use substances. Impairments were of similar magnitude compared to persons with schizophrenia. Delineation of a specific cognitive profile in SIP was precluded by lack of literature with comparable study designs and outcomes. Variation in visual-based cognition may be a distinct feature of SIP, but this requires further investigation. More rigorously controlled studies of cognition in SIP are needed to inform differential diagnosis and identify the unique clinical needs of this population.

Keywords: Addiction; Cognition; Neuropsychology; Psychiatric disorder; Psychotic disorders; Schizophrenia; Substance use.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Central Nervous System Stimulants*
  • Cognition
  • Cognitive Dysfunction* / etiology
  • Humans
  • Neuropsychological Tests
  • Psychotic Disorders* / diagnosis
  • Schizophrenia* / diagnosis

Substances

  • Central Nervous System Stimulants